Pfizer Company Profile (NYSE:PFE)

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Friday, April 28th. Stockholders of record on Friday, May 12th will be paid a dividend of $0.32 per share on Thursday, June 1st. This represents a $1.28 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Wednesday, May 10th. View Pfizer's Dividend History.

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The business's revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Pfizer.

Pfizer updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $53.15 billion.

18 analysts have issued 12 month target prices for Pfizer's shares. Their forecasts range from $31.00 to $53.00. On average, they expect Pfizer's share price to reach $37.88 in the next year. View Analyst Ratings for Pfizer.

Here are some recent quotes from research analysts about Pfizer stock:

• 1. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
• 2. According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio. Pfizer’s new products like Ibrance should do well and drive revenues in 2017 while cost-savings and share buybacks should boost earnings. Pfizer’s shares surpassed that of large-cap pharma industry in the past one year. The company has a positive record of earnings surprises in recent quarters. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. Estimates have declined slightly ahead of its Q4 earnings release." (1/25/2017)
• 3. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Pfizer saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 46,876,487 shares, an increase of 1.0% from the April 28th total of 47,334,456 shares. Based on an average daily trading volume, of 24,677,510 shares, the short-interest ratio is presently 1.9 days. Approximately 0.8% of the company's shares are short sold.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis AG (NVS), Merck & Co. (MRK), Sanofi SA (SNY), AbbVie (ABBV), GlaxoSmithKline plc (GSK), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Eli Lilly and Co (LLY), Shire PLC (SHPG), GW Pharmaceuticals PLC- (GWPH), Aerie Pharmaceuticals (AERI), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Retrophin (RTRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI) and Zogenix (ZGNX).

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.50%), Vanguard Group Inc. (6.88%), State Street Corp (5.37%), Wellington Management Group LLP (1.23%), Bank of New York Mellon Corp (1.18%) and State Farm Mutual Automobile Insurance Co. (1.00%). Company insiders that own Pfizer stock include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., APG Asset Management N.V., Parametric Portfolio Associates LLC, Canada Pension Plan Investment Board, Lazard Asset Management LLC, Ameriprise Financial Inc., Caisse DE Depot ET Placement DU Quebec and PNC Financial Services Group Inc.. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Pfizer's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Cibc World Markets Corp, Vanguard Group Inc., Swiss National Bank, Wellington Management Group LLP, Morgan Stanley and Geode Capital Management LLC. View Insider Buying and Selling for Pfizer.

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Pfizer stock can currently be purchased for approximately $32.14.